Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
August 04 2020 - 9:30AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced the appointment of Robert J. Spiegel, MD, FACP, a
renowned biotech and pharmaceutical executive, to its Board of
Directors.
“We are thrilled to add an industry executive with Dr. Spiegel’s
deep drug development expertise to our Board of Directors,” said
Dr. Johnson Lau, Chairman and Chief Executive Officer of
Athenex. “Dr. Spiegel is a seasoned leader and has a strong
track record of innovation and successful NDA approvals at both
large cap pharmas and smaller biotechs. His contribution will
be instrumental as we advance our pipeline programs and invest in
future label expansion opportunities.”
Dr. Spiegel was most recently Chief Medical Officer of PTC
Therapeutics and prior to that he was Chief Medical Officer at
Schering-Plough. During his tenure of 26 years at Schering,
Dr. Spiegel chaired the oncology development team for over 10 years
and oversaw over 30 successful New Drug Applications. Dr.
Spiegel is an Associate Professor of Medicine at Weill Cornell
Medical College. Dr. Spiegel also consults as an Advisor to
Warburg Pincus and serves on the Boards of Geron Corporation,
Cyclacel Pharmaceuticals, and Ayala Pharmaceuticals.
“Athenex has an innovative Orascovery platform that can
potentially transform chemotherapies and improve patients' lives.
I am excited to join the Athenex Board of Directors and to
help the Company further advance their broad clinical pipeline and
bring important innovative products to cancer patients,” said Dr.
Spiegel.
Athenex also announces today that Mr. John Koh has resigned from
the company’s Board of Directors. Mr. Koh is stepping down in order
to permit the Company to expand the breadth and depth of the
pharmaceutical industry expertise of its Board during a critical
period of the Company’s growth. The Athenex team and the Board of
Directors thanks Mr. Koh for his contribution and commitment to the
Company since joining the Board of Directors in April 2019.
About Athenex, Inc.Founded in 2003, Athenex,
Inc. is a global clinical stage biopharmaceutical company dedicated
to becoming a leader in the discovery, development and
commercialization of next generation drugs for the treatment of
cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global
Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery,
based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3)
T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine
deprivation therapy. Athenex’s employees worldwide are dedicated to
improving the lives of cancer patients by creating more active and
tolerable treatments. Athenex has offices in Buffalo and
Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago,
Illinois; Hong Kong; Taipei, Taiwan; multiple locations in
Chongqing, China; Manchester, UK; Guatemala City, Guatemala and
Buenos Aires, Argentina. For more information, please visit
www.athenex.com.
CONTACTSAthenex, Inc.: Daniel Lang, MD
Corporate Development and Corporate Communications
Email: danlang@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024